Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Natacha Bastien"'
Autor:
Étienne de Villers-Sidani, Patrice Voss, Natacha Bastien, J. Miguel Cisneros-Franco, Shamiza Hussein, Nancy E. Mayo, Nils A. Koch, Alexandre Drouin-Picaro, François Blanchette, Daniel Guitton, Paul S. Giacomini
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
A growing body of evidence supports the link between eye movement anomalies and brain health. Indeed, the oculomotor system is composed of a diverse network of cortical and subcortical structures and circuits that are susceptible to a variety of dege
Externí odkaz:
https://doaj.org/article/600b9de7f0ee45a49c4ad395b1d32a77
Autor:
Haissam Haddad, MD, FRCPC, Sebastien Bergeron, MD, FRCPC, Andrew Ignaszewski, MD, FRCPC, Gregory Searles, MD, FRCPC, Driss Rochdi, PhD, Priyanka Dhage, MStat, Natacha Bastien, PhD
Publikováno v:
CJC Open, Vol 2, Iss 5, Pp 344-353 (2020)
Background: To determine the effectiveness of sacubitril/valsartan 97/103 mg twice daily (b.i.d.) on tolerability, safety, and quality of life (QoL) in Canadian patients with heart failure with reduced ejection fraction in a real-life setting. Method
Externí odkaz:
https://doaj.org/article/1635be09af5841358392d3f77e0ec924
Autor:
Sameer Chhibber, Calum S. Neish, Natacha Bastien, Jessica Lanthier-Martel, Zhiyi Lan, G. Sarah Power, Driss Rochdi, Jonathan Gladstone, Jagdeep Minhas
Publikováno v:
Headache: The Journal of Head and Face Pain. 62:78-88
OBJECTIVE To describe the real-world treatment persistence (defined as the continuation of medication for the prescribed treatment duration), demographics and clinical characteristics, and treatment patterns for patients prescribed erenumab for migra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caa9192141b6c0c0fbfba44f79b6c72a
https://doi.org/10.1111/head.14218
https://doi.org/10.1111/head.14218
Autor:
Driss Rochdi, Natacha Bastien, Sebastien Bergeron, Gregory Searles, Haissam Haddad, Priyanka Dhage, Andrew Ignaszewski
Publikováno v:
CJC Open
CJC Open, Vol 2, Iss 5, Pp 344-353 (2020)
CJC Open, Vol 2, Iss 5, Pp 344-353 (2020)
Background: To determine the effectiveness of sacubitril/valsartan 97/103 mg twice daily (b.i.d.) on tolerability, safety, and quality of life (QoL) in Canadian patients with heart failure with reduced ejection fraction in a real-life setting. Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43c4a96cf8d0b33d1419d1b82287379c
https://doi.org/10.1016/j.cjco.2020.04.007
https://doi.org/10.1016/j.cjco.2020.04.007